China backs Trump’s Ukraine peace bid at G20 as U.S. allies rally behind Zelenskyy

China backs Trump’s Ukraine peace bid at G20 as U.S. allies rally behind Zelenskyy


Wang Yi, China’s foreign minister, at the G20 meeting in South Africa on Feb. 20, 2025.

Phill Magakoe | Afp | Getty Images

BEIJING, Feb 21 (Reuters) – China came out in support of U.S. President Donald Trump’s bid to strike a deal with Russia to end the war in Ukraine, at a G20 meeting in South Africa on Thursday, while U.S. allies rallied around Ukrainian President Volodymyr Zelenskiy.

Less than a month into his presidency, Trump has upended U.S. policy on the war, scrapping a campaign to isolate Moscow with a phone call to Russian President Vladimir Putin and talks between senior U.S. and Russian officials that have sidelined Ukraine.

Trump on Wednesday then denounced Zelenskiy as a “dictator,” prompting statements of support for the Ukrainian president from G20 members such as Australia, Germany and the United Kingdom.

“China supports all efforts conducive to peace (in Ukraine), including the recent consensus reached between the United States and Russia,” Wang Yi told other G20 foreign ministers gathered in Johannesburg, according to a statement from his ministry.

“China is willing to continue playing a constructive role in the political resolution of the crisis,” he added.

Wang did not reiterate the point he made at the Munich Security Conference last Friday that all stakeholders in the Russia-Ukraine conflict should participate in any peace talks.

“China is generally happy to see the easing of relations between the United States and Russia and the shift of the Ukrainian crisis to a political solution, but will pay close attention to the direction of negotiations and the direction of easing of U.S.-Russian relations,” said Cui Hongjian, head of European Union studies at Beijing Foreign Studies University.

“If China participates in mediation, it can reduce the risk of the United States using the easing of relations with Russia to harm China’s interests.”

He added that Wang Yi’s previous remark that all stakeholders should be included in talks covers not only Ukraine and Europe, but also China and Global South countries.

Global South countries represent developing, emerging or lower-income nations, mostly in the southern hemisphere.

However, other analysts were sceptical of China’s substantive involvement beyond rhetorical statements at this stage, given Beijing’s aversion to taking geopolitical risks.

“China is happy not to be called on the spot to deliver because they don’t know what Trump will demand,” said Alexander Gabuev, director of the Carnegie Russia Eurasia Center.

“Trump wanted China’s involvement initially but now he’s spoken to Putin. He is under the impression that he doesn’t need China to get a deal with Putin and Putin will give him a perfect and better deal going forward.”



Source

U.S. and Iran haven’t backed ceasefire idea as Trump’s Hormuz Strait deadline nears
World

U.S. and Iran haven’t backed ceasefire idea as Trump’s Hormuz Strait deadline nears

US President Donald Trump disembarks from Air Force One upon arrival at Joint Base Andrews in Maryland, March 23, 2026. Saul Loeb | Afp | Getty Images President Donald Trump has not backed an idea for a 45-day ceasefire that would take effect before his upcoming deadline for Iran to either reopen the Strait of […]

Read More
S&P 500 rises as investors await possible Iran and U.S. ceasefire: Live updates
World

S&P 500 rises as investors await possible Iran and U.S. ceasefire: Live updates

Traders work on the floor of the New York Stock Exchange (NYSE) at the opening bell in New York on April 2, 2026. Charly Triballeau | Afp | Getty Images The S&P 500 rose on Monday following a winning week as oil prices pulled back, with traders weighing the odds that the U.S.-Iran war could […]

Read More
Neurocrine expands into metabolic diseases with .9 billion Soleno buyout
World

Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout

Piotr Swiat | Lightrocket | Getty Images Neurocrine Biosciences will acquire rare-disease drugmaker ⁠Soleno Therapeutics for $2.9 billion in cash, the companies said on Monday, marking the neuroscience-focused ​drugmaker’s expansion into ​metabolic disorders. The deal ​gives Neurocrine access to Vykat XR, the first drug approved in the U.S. to treat hyperphagia associated with Prader-Willi syndrome, […]

Read More